Friday, February 7, 2014


Aurobindo Pharma Limited
3Q 2013-14 Unaudited Results

Consolidated Financials
during Q3FY2013-14 on Y-o-Y basis:

Total Operating Income up by 36.3% to Rs.2140.6Cr (Rs.1570.1Cr)
Operating Profit (EBIDTA) before Fx improves to 30.1% (16.5%)
Operating Profit (EBIDTA) before Fx up 148.5% to Rs.643.8Cr (Rs.259.1Cr)
PBT before Fx up by 220.7% to Rs.547.7Cr (Rs.170.8Cr)
PAT up by 354.8% to  Rs.417.5Cr (Rs.91.8Cr)
Basic & diluted EPS (not annualized) is Rs.14.34 and  Rs.14.32 respectively for the current quarter.
Formulation Sales up by 57.5% to  Rs.1436.1 Cr (Rs.911.8 Cr)
API Sales up by 12.8% to Rs.744.5 Cr (Rs.660.2 Cr)
Formulations Sales constitute 65.9% (58.0%) and API 34.1% (42.0%) of gross sales
The EBITDA during the quarter has improved by 13.6% on Y-o-Y basis due to improved business mix resulting in decrease in materials consumption, staff costs other expenses to net sales by 9.1%, 0.9% and 5.6% respectively and decline in dossier income by 2.0%
Commenting on the Company’s performance, Mr. N. Govindarajan, MD of the company said:
“We have had a robust quarter driven by our sustaining base business along with successful launches in US, translating into better top and bottom line We are confident to sustain the momentum as we foray into strengthening our access into markets, products and technology platforms where we are not dominantly present as we consolidate on our existing businesses”

Global Regulatory Filings

Filings               Q3 FY13-14 :: Cumulative Filings
ANDAs (USA)               14             308
DMFs (USA)                 1               176
Formulations Dossiers in other key advanced markets (incl. Multiple registration into
EU. South Africa, Australia and Canada)81       1940
API DMF/COS filings in other key regulated markets ::28   :: 2214
Patents                        6              551

Following approvals in USA (188 cumulative approvals including 25 tentative by USFDA), South Africa (66 cumulative approvals by MCC-SA), Australia (47 cumulative approvals by TGA) and Canada (45 cumulative approvals by Health Canada)) were received during the quarter ended 31st December 2013:


1. Acyclovir Sodium Injection 500mg/10mL (50mg/mL) & 1000mg/20mL (50mg/mL) (Treatment of Herpes, Shingles): Final
2. Bupivacaine Hydrochloride Injection USP 0.25% (2.5mg/mL), 0.5% (5mg/mL) & 0.75% (7.5mg/mL) (Anesthetic): Final
3. Finasteride Tablets USP 1mg (Benign prostatic hyperplasia): Final (Earlier TA)
4. Lamivudine+Tenofovir Disoproxil Fumarate Tablets, Co-packaged with Nevirapine Tablets USP 300mg/300mg/200mg (ARV): Final
5. Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate & Amphetamine Sulfate Tablets 5mg, 7.5mg,
10mg, 12.5mg, 15mg, 20mg & 30mg (ADHD and Narcolepsy): Final
6. Duloxetine Hydrochloride Delayed Release Capsules 20mg, 30mg & 60mg (CNS): Final

South Africa

1. Fluconazole Capsules 50mg, 100mg, 150mg, 200mg
2. Escitalopram Oxalate Tablets 5mg, 10mg, 20mg


1. Candesartan/Hydrochlorothiazide Tablets
16/12.5mg, 32/12.5mg and 32/25mg


1. Sildenafil Tablets 25mg, 50mg, 100mg
2. Valsartan Tablets 40mg, 80mg, 160mg, 320mg
3. Lamivudine/Zidovudine Tablets 150/300mg
4. Pantoprazole Gastro Resistant Tablets 40mg
5. Clopidogrel Tablets 75mg
6. Efavirenz Tablets 600mg

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (, headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company’s robust product portfolio is spread over 6
major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

* * * E N D * * *

No comments:

Post a Comment